124I-JS001

124I-JS001 is a radiolabeled form of the humanized monoclonal antibody JS001 (toripalimab), which targets the programmed death-1 (PD-1) receptor. The drug is labeled with iodine-124 for use as a PET imaging agent to noninvasively assess PD-1 expression in tumors. This allows for molecular imaging of PD-1–positive tumors and may help identify patients who could benefit from anti-PD-1 immunotherapy such as toripalimab itself. The mechanism of action involves specific binding to the PD-1 receptor on T cells, enabling visualization of immune checkpoint expression in vivo using PET/CT or PET/MR modalities[1][2][3]. Developed primarily for research and diagnostic purposes rather than direct therapeutic use, 124I-JS001 has been evaluated in both preclinical models and early human studies for its safety profile and ability to detect high PD-1 expression in melanoma lesions[1].

Other names

toripalimab radiolabeled with iodine-124124I-toripalimab